NEOS Investment Management LLC Buys Shares of 6,111 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

NEOS Investment Management LLC purchased a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 6,111 shares of the biopharmaceutical company’s stock, valued at approximately $240,000.

A number of other large investors have also recently made changes to their positions in the stock. FMR LLC lifted its position in Xenon Pharmaceuticals by 2.2% during the third quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company’s stock valued at $272,349,000 after purchasing an additional 149,511 shares during the period. Walleye Capital LLC purchased a new stake in Xenon Pharmaceuticals during the 3rd quarter valued at $4,132,000. Erste Asset Management GmbH bought a new position in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $1,932,000. HighVista Strategies LLC boosted its stake in shares of Xenon Pharmaceuticals by 1.4% in the 3rd quarter. HighVista Strategies LLC now owns 73,762 shares of the biopharmaceutical company’s stock worth $2,904,000 after buying an additional 1,047 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Xenon Pharmaceuticals by 144.2% in the third quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company’s stock worth $100,506,000 after acquiring an additional 1,507,135 shares during the period. 95.45% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 22,468 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,258,340.40. This represents a 41.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 5.52% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $33.55 on Tuesday. The stock has a market cap of $2.57 billion, a PE ratio of -11.90 and a beta of 1.26. Xenon Pharmaceuticals Inc. has a 1 year low of $32.70 and a 1 year high of $46.00. The firm has a fifty day moving average price of $37.62 and a 200-day moving average price of $39.70.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05. On average, research analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on XENE. StockNews.com raised Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. William Blair restated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Royal Bank of Canada reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.38.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.